Clinical Determinants of Extraurinary Tract Recurrence and Survival after Radical Surgery for pT2 Upper Tract Urothelial Carcinoma

Simple Summary Although upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy in Western countries, recurrence and distant metastasis are common even after definitive surgery. Many prognostic factors have been identified from previous studies, allowing clinicians to better stratify risk to select patients for perioperative systemic therapy; however, the applicability of adjuvant chemotherapy for patients with stage II UTUC after radical surgery remains unclear. In this study, we found that patients with primary tumor location at ureter or renal pelvis plus synchronous ureter had more frequent disease relapse and worse long-term oncological outcomes than other patients. Male sex, older age, history of previous bladder cancer, and positive surgical margins remain important unfavorable prognostic factors for recurrence and survival. Additional treatment and closer surveillance in patients with these negative prognostic factors are warranted despite complete pathological removal of the tumor. Abstract Background: Oncologic outcomes for pT2N0M0 upper tract urothelial carcinoma (UTUC) after nephroureterectomy are not well defined, with most previous studies focused on a heterogeneous population. Therefore, we aimed to investigate the clinical determinants of extraurinary tract recurrence and survival after radical surgery in patients with localized UTUC. Methods: We retrospectively identified 476 patients with pT2N0M0 UTUC who underwent radical nephroureterectomy or ureterectomy between October 2002 and March 2022. To evaluate the prognostic impact, patients were divided into renal pelvic, ureteral, and both-region (renal pelvis plus synchronous ureter) groups based on tumor location. The outcomes included recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). Associations were evaluated using multivariable Cox regression analyses for prognostic factors and Kaplan–Meier analyses for survival curves. Results: The renal pelvic, ureteral, and both-region groups consisted of 151 (31.7%), 314 (66.0%), and 11 (2.3%) patients, respectively. Kaplan–Meier analyses comparing the three tumor types showed significant differences in 5-year RFS (83.6% vs. 73.6% vs. 52.5%, p = 0.013), CSS (88.6% vs. 80.7% vs. 51.0%, p = 0.011), and OS (83.4% vs. 70.1% vs. 45.6%, p = 0.002). Multivariable analyses showed that age >60 years, previous bladder cancer history, ureteral involvement (ureteral and both-regional groups), and positive surgical margins were significant negative prognostic factors for the studied outcomes. Conclusions: Patients with pT2 UTUC and presence of ureteral involvement had more frequent disease relapse. Subsequent adjuvant therapy regimens and close follow-up in patients with negative prognostic factors are warranted despite complete pathological removal of the tumor.

[1]  Miao-Fen Chen,et al.  Perioperative Complications and Oncologic Outcomes after Radical Cystectomy in End-Stage Renal Disease Patients with Bladder Cancer Obtained Using a Standardized Reporting System , 2022, Cancers.

[2]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[3]  R. Autorino,et al.  Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry , 2021, The Journal of urology.

[4]  Miao-Fen Chen,et al.  Treatment Strategy for Dialysis Patient with Urothelial Carcinoma , 2021, Diagnostics.

[5]  N. Powe,et al.  New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.

[6]  N. Powe,et al.  A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  N. Bojanić,et al.  Prognostic value of Balkan endemic nephropathy and gender on upper tract urothelial carcinoma outcomes after radical nephroureterectomy: A cohort study. , 2021, Urologic oncology.

[8]  D. Matsuda,et al.  Oncologic Outcomes of Salvage Chemotherapy in Patients with Recurrent or Metastatic Lesions after Radical Nephroureterectomy: A Multi-Institutional Retrospective Study , 2020, Chemotherapy.

[9]  Steven L. Chang,et al.  Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. , 2020, European urology.

[10]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.

[11]  J. Donovan,et al.  Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial , 2020, The Lancet.

[12]  S. Boorjian,et al.  Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  S. Shariat,et al.  Differential Effect of Sex on Outcomes After Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. , 2020, The Journal of urology.

[14]  Yen-Ta Chen,et al.  Gender effect on the oncologic outcomes of upper urinary tract urothelial carcinoma in Taiwan , 2020, International Urology and Nephrology.

[15]  Wen-Cheng Chen,et al.  Chang Gung Research Database: A multi-institutional database consisting of original medical records , 2017, Biomedical journal.

[16]  Yen-Ta Chen,et al.  Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016;70:1052-68: P , 2017, European Urology.

[17]  M. Babjuk,et al.  Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC) , 2017, World Journal of Urology.

[18]  M. Babjuk,et al.  Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. , 2016, European urology.

[19]  K. Kihara,et al.  Ureteral Involvement Is Associated with Poor Prognosis in Upper Urinary Tract Urothelial Carcinoma Patients Treated by Nephroureterectomy: A Multicenter Database Study. , 2016, European urology focus.

[20]  Y. Horiguchi,et al.  Prediction of renal function after nephroureterectomy in patients with upper tract urothelial carcinoma. , 2015, Japanese journal of clinical oncology.

[21]  H. Taubert,et al.  Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma. , 2015, Anticancer Research.

[22]  S. Shariat,et al.  Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study , 2015, World Journal of Urology.

[23]  David A. Green,et al.  Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. , 2012, European urology.

[24]  F. Saint,et al.  Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. , 2011, European urology.

[25]  M. Jinzaki,et al.  Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. , 2011, The Journal of urology.

[26]  F. Montorsi,et al.  Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. , 2011, Urology.

[27]  K. Chamie,et al.  Effect of age on transitional cell carcinoma of the upper urinary tract: presentation, treatment, and outcomes. , 2009, Urology.

[28]  K. Bensalah,et al.  Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. , 2010, European urology.

[29]  K. Bensalah,et al.  Advanced patient age is associated with inferior cancer‐specific survival after radical nephroureterectomy , 2009, BJU international.

[30]  F. Montorsi,et al.  Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. , 2009, The Journal of urology.

[31]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[32]  F. Hamdy,et al.  Behavior of urothelial carcinoma with respect to anatomical location. , 2007, The Journal of urology.